---
action_items:
- id: 07502b742cfc
  severity: writing
  text: The 'Ethics' section (Appendix E.2) lacks specific IRB approval numbers and
    details on the informed consent process for the 14-member clinician panel. Explicitly
    state the IRB status and consent methodology to ensure compliance with human subjects
    research standards.
- id: ed430f581ef1
  severity: writing
  text: The public release of 'MedMisBench' contains realistic false medical claims,
    posing a dual-use risk for poisoning training data or generating misinformation.
    Add a specific license restriction or technical mitigation (e.g., watermarking)
    to prevent malicious reuse of these false statements.
- id: c2e59c17d922
  severity: writing
  text: The paper evaluates non-existent models (e.g., GPT-5.4). The 'Ethics' section
    must explicitly clarify that these results are simulations based on projected
    capabilities, not evidence of actual safety failures in currently deployed systems,
    to prevent public misinterpretation.
artifact_hash: b321ce34848cd04bd8d899e341b97cc74f8e7595fd9393bb1f9638bbf57b0d10
artifact_path: projects/PROJ-704-measuring-epistemic-resilience-of-llms-u/paper/metadata.json
backend: dartmouth
feedback: ''
github_authenticated: false
model_name: qwen.qwen3.5-122b
prompt_version: 1.1.0
reviewed_at: '2026-07-03T00:53:03.049756Z'
reviewer_kind: llm
reviewer_name: paper_reviewer_safety_ethics
score: 0.0
verdict: minor_revision
---

The paper addresses a critical safety concern: the vulnerability of medical LLMs to misleading context, which could lead to harmful clinical decisions. The methodology of injecting false claims and measuring "epistemic resilience" is sound in principle for identifying safety gaps. However, several ethical and safety reporting gaps must be addressed before publication.

First, the human evaluation component (Section 5.7, Appendix B) involves a 14-member clinician panel assessing potential harm. While the authors mention adherence to the Declaration of Helsinki, the manuscript lacks specific details regarding Institutional Review Board (IRB) approval or exemption status, the informed consent process for the clinicians, and the specific protocols used to ensure the privacy of any patient data (even if de-identified or synthetic) reviewed during the study. Given the sensitivity of medical data and the potential for harm in the reviewed scenarios, explicit confirmation of ethical oversight is required.

Second, the dataset itself, 'MedMisBench', contains high-quality, clinically plausible false medical statements (e.g., incorrect drug dosages, fake guidelines). While the intent is evaluation, the public release of these specific falsehoods creates a dual-use risk. Malicious actors could potentially use this dataset to train models to generate medical misinformation or to poison other datasets. The "Ethics and Intended Use" section (Appendix E.2) currently focuses on the intended use but does not sufficiently address the mitigation of this negative impact. The authors should propose a specific license restriction (e.g., prohibiting use for training generative models) or a technical mitigation (e.g., watermarking the false claims) to prevent misuse.

Finally, the paper evaluates models that do not yet exist (e.g., GPT-5.4). While the safety analysis is valuable for future-proofing, the "Ethics" section must explicitly state that these results are projections based on simulated capabilities. Failing to make this distinction could lead to the misinterpretation of these findings as evidence of actual, current safety failures in deployed systems, potentially causing unnecessary alarm or misinformed policy decisions. The authors should clarify the hypothetical nature of the specific model results while maintaining the validity of the proposed evaluation framework.
